Silicon Nanoparticle Delivery System for Controlled Release of Nucleic Acids Including siRNA and mRNA

The USPTO published patent application US20260096997A1 for a silicon nanoparticle-based delivery system designed for controlled release of nucleic acids including siRNA and mRNA. The composition includes at least 50% silicon by weight, at least one amino acid, and at least one lipid. CPC classifications indicate relevance to pharmaceutical preparations (A61K 9/5115, A61K 9/127), nucleic acid therapeutics (A61K 31/713), and ophthalmological applications (A61P 27/02).

Affected parties in pharmaceutical manufacturing, biotechnology, and drug delivery technology sectors should monitor this patent application for potential future exclusivity claims in nucleic acid delivery systems. The application represents one of many entries in the expanding field of nanoparticle-based therapeutic delivery platforms targeting ocular and other therapeutic applications.